↓ Skip to main content

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models

Overview of attention for article published in Journal of Hematology & Oncology, June 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)

Mentioned by

patent
4 patents

Citations

dimensions_citation
58 Dimensions

Readers on

mendeley
98 Mendeley